ATE407701T1 - Wässrige proteinformulierung mit verzögerter freigabe - Google Patents

Wässrige proteinformulierung mit verzögerter freigabe

Info

Publication number
ATE407701T1
ATE407701T1 AT02780626T AT02780626T ATE407701T1 AT E407701 T1 ATE407701 T1 AT E407701T1 AT 02780626 T AT02780626 T AT 02780626T AT 02780626 T AT02780626 T AT 02780626T AT E407701 T1 ATE407701 T1 AT E407701T1
Authority
AT
Austria
Prior art keywords
delayed release
protein formulation
release protein
aqueous delayed
aqueous
Prior art date
Application number
AT02780626T
Other languages
English (en)
Inventor
Basant Sharma
Renzhe Jin
Sunitha Rudolph
Wing Cheung
Selima Begum
Marian Kelley
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Application granted granted Critical
Publication of ATE407701T1 publication Critical patent/ATE407701T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT02780626T 2001-11-07 2002-10-25 Wässrige proteinformulierung mit verzögerter freigabe ATE407701T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/037,369 US6818613B2 (en) 2001-11-07 2001-11-07 Aqueous sustained-release formulations of proteins

Publications (1)

Publication Number Publication Date
ATE407701T1 true ATE407701T1 (de) 2008-09-15

Family

ID=21893975

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02780626T ATE407701T1 (de) 2001-11-07 2002-10-25 Wässrige proteinformulierung mit verzögerter freigabe

Country Status (19)

Country Link
US (3) US6818613B2 (de)
EP (1) EP1441771B1 (de)
JP (1) JP2005514394A (de)
CN (1) CN1612752A (de)
AR (1) AR037260A1 (de)
AT (1) ATE407701T1 (de)
AU (1) AU2002343666B2 (de)
BR (1) BR0213992A (de)
CA (1) CA2465890A1 (de)
CY (1) CY1110271T1 (de)
DE (1) DE60228864D1 (de)
DK (1) DK1441771T3 (de)
ES (1) ES2312633T3 (de)
MX (1) MXPA04004367A (de)
MY (1) MY136952A (de)
PT (1) PT1441771E (de)
SI (1) SI1441771T1 (de)
TW (1) TWI332845B (de)
WO (1) WO2003053471A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ．ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
BRPI0407649A (pt) * 2003-02-28 2006-02-21 Ares Trading Sa formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1537876A1 (de) * 2003-12-01 2005-06-08 BioGeneriX AG Formulierung einer Erythropoietin Lösung
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
EP1814574A4 (de) 2004-10-27 2009-08-05 Univ Denver Analoga des adrenocorticotropen hormons und entsprechende verfahren
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
CN101400367A (zh) * 2006-02-02 2009-04-01 瑞纳神经科学公司 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法
CA2637707A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
JP2010534194A (ja) * 2007-06-15 2010-11-04 チューリッヒ大学 神経系障害の新規な処置法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009083203A2 (de) * 2007-12-28 2009-07-09 Heraeus Kulzer Gmbh Topische anwendung und formulierung von erythropoietin für die wundheilung der haut
US8357179B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8795345B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8795317B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Embolic obstruction retrieval devices and methods
US20110009941A1 (en) * 2009-07-08 2011-01-13 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8529596B2 (en) 2009-07-08 2013-09-10 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8357178B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
KR101680420B1 (ko) 2011-02-04 2016-11-28 콘센트릭 메디칼, 인크. 혈관 및 신체 관 치료 장치 및 방법
MX421100B (es) 2011-07-01 2025-02-10 Biogen Ma Inc Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
TWI897843B (zh) * 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
CN120420414A (zh) * 2024-02-04 2025-08-05 南京汉欣医药科技有限公司 含有人工合成的促皮质素类似物的组合物、其制备方法以及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
EP0062827B1 (de) * 1978-06-16 1986-07-23 Kyowa Hakko Kogyo Co., Ltd Benzamidderivate
EP0090837A1 (de) 1981-10-08 1983-10-12 BERG, Kurt Frimann Verfahren und zusammensetzung zum behandeln von kranken die an interferon empfindlichen krankheiten leiden
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
ES8404783A1 (es) * 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
JPS604186A (ja) * 1983-06-21 1985-01-10 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン化合物
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4717717A (en) 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
JP2001515457A (ja) * 1995-06-07 2001-09-18 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 凝集安定化生理活性物質放出用装置
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
CA2244664C (en) 1996-02-09 2008-06-03 Amgen Inc. Composition comprising interleukin-1 inhibitor and controlled release polymer
IL128229A0 (en) 1996-08-02 1999-11-30 Ortho Mcneil Pharm Inc Polypeptides having a single covalently bound n-terminal water-soluble polymer
ATE341625T1 (de) 1997-07-23 2006-10-15 Roche Diagnostics Gmbh Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
DE69726571T2 (de) 1997-09-01 2004-11-04 Aventis Pharma Deutschland Gmbh Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
DE69933216T2 (de) 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham Erythropoietin-analog-menschliches serum-albumin fusionsprotein
DE69936212T2 (de) 1998-09-04 2008-01-24 Scios Inc., Sunnyvale Hydrogelzusammensetzungen mit kontrollierter Freigabe für die Verabreichung von Wachstumsfaktoren
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CO5160256A1 (es) 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
ATE401908T1 (de) 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins

Also Published As

Publication number Publication date
PT1441771E (pt) 2008-10-29
EP1441771B1 (de) 2008-09-10
CA2465890A1 (en) 2003-07-03
US20030148938A1 (en) 2003-08-07
DE60228864D1 (de) 2008-10-23
US6818613B2 (en) 2004-11-16
AU2002343666B2 (en) 2007-04-05
CN1612752A (zh) 2005-05-04
ES2312633T3 (es) 2009-03-01
MXPA04004367A (es) 2005-05-16
US20030181361A1 (en) 2003-09-25
TW200303215A (en) 2003-09-01
WO2003053471A1 (en) 2003-07-03
TWI332845B (en) 2010-11-11
JP2005514394A (ja) 2005-05-19
EP1441771A1 (de) 2004-08-04
HK1066468A1 (en) 2005-03-24
AR037260A1 (es) 2004-11-03
BR0213992A (pt) 2004-08-31
US20050164927A1 (en) 2005-07-28
SI1441771T1 (sl) 2009-02-28
AU2002343666A1 (en) 2003-07-09
DK1441771T3 (da) 2009-01-05
US7282480B2 (en) 2007-10-16
MY136952A (en) 2008-12-31
CY1110271T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
DE60228864D1 (de) Wässrige proteinformulierung mit verzögerter freigabe
ATE506064T1 (de) Analgetika mit verzögerter wirkstoffabgabe
NO20033143L (no) Farmasoytisk preparat
DE60219383D1 (de) Wässrige Beschichtungszusammensetzung
CY2014009I1 (el) Παρασιτοκτονα σκευασματα
ATE495731T1 (de) Amphetaminsalz-formulierung mit verzögerter wirkstofffreigabe
NO20034026D0 (no) Nytt preparat
DE50202890D1 (de) Anhängekupplung
EP1391209A4 (de) Proteinzubereitung
ATE267592T1 (de) Klare wässrige anästhesierende zusammensetzung
EP1460900A4 (de) Sezernierte humanproteine
NO20034695L (no) Nytt preparat
NO20025805D0 (no) Farmasöytisk preparat
DE60103683D1 (de) Wässrige Pestizidzusammensetzung
DE60229399D1 (de) Hgf-hydrogel-zubereitungen mit verzögerter freisetzung
NO20033829D0 (no) Antiviralt preparat
DE60234592D1 (de) Wässrige zusammensetzung
DK1361791T3 (da) Agrokemisk formulering
BR0113783B1 (pt) Composição aquosa
NO20023392D0 (no) Preparat
FR2821754B1 (fr) Descenceur autobloquant
NO20026215D0 (no) Nytt hormonpreparat
ATA2892002A (de) Beschlag
DE10293967D2 (de) Verbindungsbeschlag
DE60223695D1 (de) Aminosäure-modulierte dosierform mit verlängerter freisetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1441771

Country of ref document: EP